Lantern Pharma Completes Phase 1a Trial of LP-184

Lantern Pharma Inc., an AI-driven oncology company, has announced the successful completion of its Phase 1a clinical trial for LP-184, one of its promising targeted cancer therapies developed through the company’s proprietary RADR® AI platform.

The study achieved all primary goals, confirming LP-184’s favorable safety and pharmacokinetic (PK) profile, along with encouraging early signals of antitumor activity. Enrollment is now complete, and several patients remain on treatment due to continued clinical benefit.

This open-label, multicenter trial enrolled 63 patients with advanced, relapsed, or refractory solid tumors, including glioblastoma multiforme (GBM). The Phase 1a study evaluated safety, tolerability, and PK, while also identifying a recommended Phase 2 dose (RP2D) for administration on Days 1 and 8 of a 21-day cycle.

Learn more